A blocking ELISA detection kit and detection method for African swine fever virus P30 protein antibody

By using antigen protection solution and monoclonal antibodies of specific components, the sensitivity and specificity of the detection of P30 protein antibody of African swine fever virus is improved, and the problems of insufficient detection sensitivity and poor antigen protection in the prior art are solved, thus achieving the More stable detection results.

CN117907592BActive Publication Date: 2024-12-03BEIJING JINNUO BAITAI BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410084059.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-19
Publication Date
2024-12-03
Estimated Expiration
2044-01-19

AI Technical Summary

Technical Problem

The existing detection methods for African swine fever virus P30 protein antibody are insufficient for detection sensitivity and specificity, and have poor antigen protection, which affects the stability of the detection results.

Method used

Antigen protection solution was prepared using specific doses of glycerol, trehalose, recombinant E. coli thioredoxin, walnut quinone and water, and combined with P30 protein P30-1 monoclonal antibody as capture antibody and P30 protein P30-2 monoclonal antibody As enzyme-labeled antibodies, antibodies form solid-phase antigens through indirect capture and coating principle, improving the sensitivity and specificity of the detection method.

Benefits of technology

It significantly improves the sensitivity, specificity and stability of the detection of P30 protein antibody of African swine fever virus, ensuring the reliability and repeatability of the test results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117907592B_ABST
    Figure CN117907592B_ABST
Patent Text Reader

Abstract

The present application relates to the technical field of biological detection, and specifically discloses a blocking ELISA detection kit and detection method for African swine fever virus P30 protein antibody. The blocking ELISA detection kit for P30 protein antibody disclosed in the present application includes a capture antibody, a standard antigen, an enzyme-labeled antibody, and an antigen protection solution; the antigen protection solution specifically includes the following concentrations of components: 80-100 parts of glycerol, 4-8 parts of trehalose, 0.1-0.2 parts of recombinant Escherichia coli thioredoxin, 0.01-0.09 parts of sodium glutamate, 0.01-0.08 parts of juglone, 0.7-1.8 parts of organic acid, and 800-900 parts of water. The present application also discloses a detection method obtained based on the above-mentioned kit. The blocking ELISA detection kit and detection method for P30 protein antibody provided in the present application have high sensitivity, specificity and repeatability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of biological detection, and specifically to a blocking ELISA detection kit and detection method for antibodies against the P30 protein of African swine fever virus. Background Art

[0002] African swine fever is an acute, severe infectious disease of domestic pigs and wild boars caused by African swine fever virus (ASFV).

[0003] At present, there is no safe and effective vaccine for the prevention and control of African swine fever. Eradicating the epidemic, eliminating the source of infection, and reducing and eliminating the occurrence of the epidemic are the main tasks of my country's prevention and control of African swine fever at present and in the future. In particular, timely discovery and accurate detection of ASFV-infected pigs and virus-carrying pigs can provide a basis for pig farms to control the spread of the epidemic, and can also provide a quarantine basis for breeding pig trade and live pig transportation. Therefore, specific, accurate and simple diagnostic technology is an urgent need for the prevention and control of African swine fever in my country. The existing ASFV detection technology is mainly pathogenic nucleic acid detection technology such as PCR, Real-time PCR, and serological detection technology such as indirect ELISA and competitive or blocking ELISA. Among them, serological detection technology is widely used in clinical production practice due to its convenience and specificity, and has become a recognized method for diagnosing subacute, chronic or subclinical infected animals.

[0004] The ASFV genome is double-stranded DNA with a size of 170 to 190 kb. The main viral genes and encoded proteins with diagnostic significance are: B646L (P72 protein), E183L (P54 protein) and CP204L (P30 protein). P30 protein is one of the important structural proteins of ASFV. It can be detected in the cytoplasm 4 hours after infection. In the protective immune response of the body, P30 protein has a certain inhibitory effect on the internalization of the virus and is related to the induction of neutralizing antibodies during infection. A variety of ELISA detection methods have been established for antibodies to this protein, but these methods mainly involve directly coating the African swine fever virus P30 protein on the ELISA plate. Due to differences in protein expression systems, there may be different degrees of low-level detection sensitivity and specificity, and the coating antigen protection is not performed in the coating process, and the stability is poor. Summary of the invention

[0005] In order to improve the sensitivity, specificity and stability of the P30 protein antibody detection method, the present application provides a blocking ELISA detection kit and a detection method for African swine fever virus P30 protein antibodies.

[0006] In a first aspect, the present application provides a blocking ELISA detection kit for African swine fever virus P30 protein antibodies, characterized in that the detection kit comprises a capture antibody, a standard antigen, an enzyme-labeled antibody, and an antigen protection solution;

[0007] The antigen protection solution specifically comprises the following components in concentrations: 80-100 parts of glycerol, 4-8 parts of trehalose, 0.1-0.2 parts of recombinant Escherichia coli thioredoxin, 0.01-0.09 parts of sodium glutamate, 0.01-0.08 parts of juglone, 0.7-1.8 parts of organic acid, and 800-900 parts of water.

[0008] In a specific embodiment, the capture antibody is the P30 protein P30-1 monoclonal antibody, and the enzyme-labeled antibody is the P30 protein P30-2 monoclonal antibody.

[0009] The present application utilizes specific amounts of glycerol, trehalose, sodium glutamate, recombinant Escherichia coli thioredoxin, juglone, organic acid and water as raw materials for antigen protection solution. After protecting the standard antigen, when detecting P30 protein antibodies in the serum sample to be tested, the detection sensitivity, specificity and stability of the detection method can be significantly improved.

[0010] The present application utilizes the P30-1 monoclonal antibody of the P30 protein as a capture antibody coated in an ELISA plate to capture a standard antigen to form a solid-phase antigen; then, an enzyme-labeled P30 protein P30-2 monoclonal antibody is utilized as a competitive antibody for the P30 protein antibody in the serum sample to be tested, thereby obtaining a detection kit for the P30 protein antibody with high detection sensitivity, strong specificity, and good repeatability.

[0011] The present application is based on the principle of indirect capture and coating, which moves the solid-phase antigen away from the carrier surface so that the antigenic determinant cluster can be fully exposed; at the same time, the indirectly coated antigen is subjected to affinity chromatography by the capture antibody, so that the purity of the standard antigen coated on the solid phase is greatly improved, thereby effectively improving the sensitivity and specificity of the detection method.

[0012] Preferably, the antigen protection solution specifically comprises components in the following concentrations: 85-95 parts of glycerol, 5-7 parts of trehalose, 0.12-0.18 parts of recombinant Escherichia coli thioredoxin, 0.05-0.09 parts of sodium glutamate, 0.01-0.04 parts of juglone, 0.9-1.5 parts of organic acid, and 800-900 parts of water.

[0013] Preferably, the organic acid is selected from one or more of acetic acid, oxalic acid and glycine.

[0014] Preferably, the organic acid is oxalic acid and glycine in a weight ratio of 7:1-3.

[0015] In a specific embodiment, the weight ratio of oxalic acid to glycine can be 7:1, 7:2, or 7:3.

[0016] In some specific embodiments, the weight ratio of oxalic acid to glycine can also be 7:1-2 or 7:2-3.

[0017] Through experimental analysis, it can be known that the present application selects oxalic acid and glycine in a weight ratio of 7:1-3 as the organic acid in the antigen protection solution, which can further improve the sensitivity and stability of the detection method.

[0018] Preferably, the detection kit further comprises a positive control serum, a negative control serum, a sample diluent, an enzyme-labeled antibody diluent, a washing solution, a blocking solution, a TMB substrate solution, and a stop solution.

[0019] Preferably, the coating concentration of the capture antibody is 0.15-2.4 μg / mL; the coating concentration of the standard antigen is 0.0375-1.2 μg / mL; and the concentration of the enzyme-labeled antibody is 62.5-2000 ng / ml.

[0020] Furthermore, the coating concentration of the capture antibody is 0.6-2.4 μg / mL; the coating concentration of the standard antigen is 0.3-1.2 μg / mL; and the concentration of the enzyme-labeled antibody is 500-2000 ng / ml.

[0021] After experimental analysis, it was found that when the coating concentration of the capture antibody reached 0.6-2.4μg / mL, the OD of the standard antigen at the same coating concentration was 450nm The value does not change much, indicating that the capture antibody has reached saturation adsorption on the ELISA plate. At the same time, when the coating concentration of the standard antigen is 0.3-1.2 μg / mL, the antigen coating reaches saturation. Therefore, the present application controls the coating concentration of the capture antibody and the standard antigen within the above range.

[0022] After experimental analysis, it is known that when the concentration of the control enzyme-labeled antibody is within the above range, the negative control serum OD 450nm Value / positive control serum OD 450nm Therefore, the concentration of the enzyme-labeled antibody is controlled within the above range.

[0023] Preferably, the sample diluent is 0.4-0.6wt% PBSA; the enzyme-labeled antibody diluent is PBSA containing 0.4-0.6wt% sucrose and a concentration of 0.4-0.6wt%; and the blocking solution is 2.5-3.5wt% BSA.

[0024] In a second aspect, the present application provides a blocking ELISA detection method for African swine fever virus P30 protein antibodies, and the detection method is obtained based on the above-mentioned blocking ELISA detection kit for African swine fever virus P30 protein antibodies.

[0025] Preferably, the blocking ELISA detection method for African swine fever virus P30 protein antibodies comprises the following steps:

[0026] (1) Antibody coating: dilute the capture antibody with carbonate buffer, add 80-120 μL to each well of the ELISA plate, incubate at 2-8° C. for 14-20 h, and discard the coating solution;

[0027] (2) Washing: Add the washing solution to each well for washing, discard the liquid in the well, and pat dry;

[0028] (3) Blocking: Add 180-220 μL of the blocking solution to each well, block at 23-27° C. for 40-80 min, discard the blocking solution, and wash according to the method of step (2);

[0029] (4) Antigen coating: dilute the standard antigen with PBST, add 80-120 μL to each well of the ELISA plate, incubate at 35-39° C. for 100-140 min, discard the liquid in the well, and wash according to the method of step (2);

[0030] (5) Protection: Add 70-130 μL of the antigen protection solution to each well, protect at 23-39° C. for 20-70 min, discard the antigen protection solution, and dry;

[0031] (6) Sample addition: dilute the positive control serum, the negative control serum, and the test serum sample using the sample diluent, add 80-120 μL to each well for incubation, then discard the liquid in the well and wash according to the method of step (2);

[0032] (7) Antibody incubation: dilute the enzyme-labeled antibody using the enzyme-labeled antibody diluent, add 80-120 μL to each well for incubation, incubate at 35-39° C. for 20-40 min, then spin dry, and wash according to the method of step (2);

[0033] (8) Color development: Add 80-120 μL of the TMB substrate solution to each well and incubate at 25° C. for color development;

[0034] (9) Termination: Add 40-60 μL of the stop solution to each well to terminate the reaction;

[0035] (10) Reading: Use an ELISA reader to read the absorbance value of each well at a wavelength of 450 nm.

[0036] When using the antigen protection solution provided in the present application, the protection temperature and protection time have an impact on the N / P value, that is, they have a great impact on the sensitivity of the detection method. Therefore, it is necessary to reasonably control the protection temperature and protection time within the above range.

[0037] Preferably, after adding the antigen protection solution in step (5), the antigen protection solution is protected at 23-27° C. for 50-70 minutes.

[0038] In summary, the technical solution of this application has the following effects:

[0039] This application is based on the principle of indirect capture and coating, and uses the P30 protein P30-1 strain monoclonal antibody as the capture antibody coated in the ELISA plate to capture the standard antigen to form a solid phase antigen; then the enzyme-labeled P30 protein P30-2 strain monoclonal antibody is used as the competitive antibody for the sample to be tested, and a blocking ELISA detection kit for African swine fever virus P30 protein antibody is obtained.

[0040] The present application utilizes the provided African swine fever virus P30 protein antibody blocking ELISA detection kit, and optimizes parameter conditions such as capture antibody coating concentration, standard antigen coating concentration, and enzyme-labeled antibody dilution to obtain an African swine fever virus P30 protein antibody blocking ELISA detection method with high sensitivity, strong specificity, and good repeatability.

[0041] The present application uses a specific amount of glycerol, trehalose, sodium glutamate, recombinant Escherichia coli thioredoxin, juglone, organic acid and water to prepare an antigen protection solution, which effectively protects the standard antigen and can effectively improve the sensitivity and stability of the P30 protein antibody detection method. In addition, the present application screens the types of organic acids in the antigen protection solution, further improving the stability of the detection method. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 This is the optimization result of the best coating concentration of the P30 protein P30-1 strain monoclonal antibody and the P30 protein antigen in Example 1. DETAILED DESCRIPTION

[0043] The present application is further described in detail below in combination with preparation examples, embodiments and performance testing experiments. These embodiments should not be construed as limiting the scope of protection claimed in the present application.

[0044] Preparation Example

[0045] Preparation Example 1

[0046] This preparation example provides a P30 protein.

[0047] The specific preparation method of P30 protein in this preparation example is:

[0048] The CP204L gene of the phosphorylated protein P30 of the African swine fever virus (Georgia strain) was codon optimized and artificially synthesized, and cloned into the pOET-1 vector to construct the recombinant plasmid pOET-P30M, which was co-transfected with flashBAC DNA into Sf9 insect cells to prepare a recombinant baculovirus expressing the P30 protein (rBV-ASFVp30M strain), and the expressed recombinant P30 protein was purified by Ni column affinity chromatography. The specific steps are as follows:

[0049] (1) Construction of recombinant plasmid pOET-P30M The DNA sequence was designed based on the CP204L gene in the ASFV genome sequence (FR682468) included in GenBank. Two restriction endonucleases, SacⅡ and PacⅠ, were added to the 5' and 3' ends of the gene sequence, respectively. A His tag was added to the 3' end. The synthesized CP204L gene sequence was inserted into the pOET-1 vector to construct the recombinant plasmid pOET-P30M, and sequencing was performed for identification.

[0050] (2) Construction of recombinant baculovirus: The correctly identified recombinant plasmid pOET-P30M and flashBAC DNA were co-transfected into Sf9 cells according to the flash BAC expression system instructions, and the cells were cultured at 27°C for 4-5 days and the supernatant was harvested to obtain the recombinant baculovirus rBV-ASFVp30M strain P0 virus.

[0051] (3) Expression and purification of recombinant P30 protein: The rBV-ASFVp30M strain was inoculated into Sf9 cells at an MOI of 1, cultured at 27°C and 120 r / min for 96 to 120 h, and the cell supernatant was harvested. The protein was purified by Ni column affinity chromatography, and the eluate was collected to obtain the purified recombinant P30 protein.

[0052] It was identified that the expressed recombinant P30 protein was 30 kDa in size and the purity of the purified P30 protein was over 90%. Western-blot identification showed that it only reacted with African swine fever virus antibody positive serum, and did not react with African swine fever virus negative serum, classical swine fever virus positive serum, porcine reproductive and respiratory syndrome virus positive serum, porcine circovirus type 2 positive serum, pseudorabies virus positive serum, porcine parvovirus positive serum, and baculovirus positive serum, showing good specificity.

[0053] Preparation Example 2-3

[0054] Preparation Example 2 provides a P30 protein P30-1 monoclonal antibody.

[0055] Preparation Example 3 provides a P30 protein P30-2 monoclonal antibody.

[0056] The specific preparation methods of the P30 protein P30-1 monoclonal antibody and the P30 protein P30-2 monoclonal antibody in the above preparation examples are as follows:

[0057] BALB / c mice were immunized with recombinant P30 protein expressed by baculovirus. After immunization for 3 times, immune spleen cells of mice were fused with myeloma cells SP2 / 0. Positive fusion cells were screened by indirect ELISA method. The positive cell lines screened were subcloned by limiting dilution method. According to the ELISA titer, affinity, antigen recognition site and specificity analysis of monoclonal antibodies, two monoclonal antibodies that recognized different antigen epitopes were selected as raw materials for this experiment, named P30-1 and P30-2. The specific operation is as follows:

[0058] (1) Mouse immunization: The recombinant P30 protein expressed by baculovirus was diluted to 300 μg / ml with PBS (0.01 mol / L, pH 7.4), emulsified with Freund's adjuvant and used to immunize 6-week-old healthy female BALB / c mice. Blood was collected from the tail after three immunizations, and the serum antibody titer was detected by indirect ELISA. Mice with high serum antibody titer were selected and boosted once 3 days before fusion. The mice were killed and the immune spleen cells were harvested.

[0059] (2) Cell fusion, screening and subcloning: SP2 / 0 cells were fused with immune spleen cells at a ratio of 1:10. When the fused cell clones grew to cover 1 / 2 of the bottom of the cell wells, the cell culture supernatant was tested by indirect ELISA. The cell wells with strong positive results by ELISA were selected and subcloned three times by limiting dilution method. The strong positive cell wells with only a single clone were selected for expansion culture.

[0060] (3) Identification of monoclonal antibodies: Monoclonal positive hybridoma cells were cultured and subjected to hybridoma cell chromosome analysis, monoclonal antibody subclass identification, and monoclonal antibody titer detection. The antigenic epitopes recognized by different monoclonal antibodies were analyzed by indirect ELISA addition test. The chromosome numbers of hybridoma cells of P30-1 and P30-2 were both 95 to 103; the heavy chain subclasses of secreted monoclonal antibodies were IgG1 and IgG2b, respectively; the two monoclonal antibodies recognized different antigenic epitopes. Finally, monoclonal antibody strains P30-1 and P30-2 were determined as the raw materials for the research.

[0061] Preparation Example 4

[0062] Preparation Example 4 provides a P30 protein P30-2 monoclonal antibody labeled with HRP enzyme.

[0063] The specific preparation method of the P30 protein P30-2 monoclonal antibody labeled with HRP enzyme (horseradish peroxidase) in this preparation example is:

[0064] The P30 protein P30-2 strain monoclonal antibody was labeled with HRP enzyme using a commercial HRP coupling kit to prepare an enzyme-labeled antibody stock solution. The enzyme-labeled monoclonal antibody was titered using a direct ELISA method, with a titer of no less than 1:20000. An equal volume of sterile glycerol was added and the solution was stored below -70°C to obtain the P30 protein P30-2 strain monoclonal antibody labeled with HRP enzyme.

[0065] Preparation Example 5-6

[0066] Preparation Example 5 provides a positive control serum.

[0067] Preparation Example 6 provides a negative control serum.

[0068] The specific preparation methods of the positive control serum and the negative control serum in the above preparation examples are as follows:

[0069] Select healthy susceptible pigs aged 2 to 4 months. They should be negative for porcine reproductive and respiratory syndrome virus ELISA antibody, negative for pseudorabies virus gB ELISA antibody, negative for classical swine fever virus neutralizing antibody, and negative for African swine fever virus antigen and antibody.

[0070] Pigs that were negative for the above antigens or antibodies were selected, and blood was randomly collected from the carotid artery of one pig to prepare African swine fever virus-negative serum, which was diluted 10 times with a diluent (sucrose dissolved in 0.5% PBSA to a final concentration of 0.2%) and a Coomassie brilliant blue solution with a final concentration of 0.002% was added to serve as the negative control serum; the remaining pigs were immunized with recombinant P30 protein, and when the serum agar titer was not less than 1:128, blood was collected from the carotid artery to separate the serum, and African swine fever virus antibody-positive serum was prepared, and the positive serum was diluted with a diluent (sucrose dissolved in 0.5% PBSA to a final concentration of 0.2%) to an agar titer of 1:32, and a 1% phenol red solution was added to a final concentration of 0.002%, which was the positive control serum.

[0071] Example

[0072] The sample diluent used in Examples 1-6 was 0.5 wt % PBSA; the enzyme-labeled antibody diluent was PBSA containing 0.5 wt % sucrose at a concentration of 0.5 wt %; and the blocking solution was 3 wt % BSA.

[0073] The preparation method of the antigen protection liquid in Example 1-6 is as follows: 90 g of glycerol, 6 g of trehalose, 0.05 g of sodium glutamate, 0.04 g of juglone, and 1.2 g of an organic acid (composed of a mixture of oxalic acid and glycine in a weight ratio of 7:2) are weighed, dissolved in 850 g of purified water and mixed evenly, the pH is adjusted to 7, and then 0.1 g of recombinant Escherichia coli thioredoxin is added, the volume is made up to 1000 mL with purified water, and stirred evenly to obtain the solution.

[0074] Example 1

[0075] This example provides the optimization of reaction conditions in the African swine fever virus P30 protein antibody blocking ELISA detection method.

[0076] The specific optimization conditions in this embodiment are: optimization of the optimal coating concentration of the P30 protein P30-1 strain monoclonal antibody and the optimal coating concentration of the P30 protein antigen, which specifically includes the following steps:

[0077] (1) Antibody coating: The monoclonal antibody of P30 protein P30-1 prepared in Preparation Example 2 was diluted to 2.4 μg / ml, 1.2 μg / ml, 0.6 μg / ml, 0.3 μg / ml, and 0.15 μg / ml respectively using 0.05 mol / L carbonate buffer at pH 9.6, and 100 μL was added to each well of a 96-well ELISA plate. The plate was incubated at 4°C for 16 h and the coating solution was discarded;

[0078] (2) Washing: Add 300 μL of PBST washing solution to each well, wash three times, discard the liquid in the well, and pat dry;

[0079] (3) Blocking: Add 200 μL of blocking solution to each well and block at 25°C for 60 min. Discard the blocking solution and wash according to the method of step (2);

[0080] (4) Antigen coating: The African swine fever virus P30 protein antigen prepared in Preparation Example 1 was diluted to 1.2 μg / mL, 0.6 μg / mL, 0.3 μg / mL, 0.15 μg / mL, 0.075 μg / mL, and 0.0375 μg / mL with PBST for capture coating. 100 μL was added to each well of a 96-well ELISA plate, and the plate was incubated at 37° C. for 120 min. The liquid in the wells was discarded, and the plate was washed according to the method of step (2);

[0081] (5) Protection: Add 100 μL of antigen protection solution to each well and protect at 25°C for 60 min. Discard the antigen protection solution and dry.

[0082] (6) Antibody incubation: dilute the HRP enzyme-labeled P30-2 monoclonal antibody prepared in Preparation Example 4 to 1 μg / ml using enzyme-labeled antibody diluent, add 100 μL to each well, incubate at 37° C. for 30 min, spin dry, and wash according to the method of step (2);

[0083] (7) Color development: Add 100 μL of TMB substrate solution to each well and develop color at 25°C for 15 min;

[0084] (8) Termination: Add 50 μL of 2 mol / L sulfuric acid stop solution to each well to terminate the color reaction;

[0085] (9) Reading: Use an ELISA reader to read the absorbance value of each well at a wavelength of 450 nm, as shown in Table 1 and Figure 1 shown.

[0086] Table 1 Optimization results of the best coating concentration of P30 protein P30-1 monoclonal antibody and P30 protein antigen

[0087]

[0088]

[0089] The maximum dilution concentration when the adsorption of P30 protein P30-1 strain monoclonal antibody on the ELISA plate reaches saturation is selected as the optimal coating concentration of P30 protein P30-1 strain monoclonal antibody; the antigen concentration when the antigen coating is saturated under the optimal coating concentration of P30 protein P30-1 strain monoclonal antibody is selected as the optimal coating concentration of P30 protein antigen.

[0090] By analyzing Table 1, when the coating concentration of P30 protein P30-1 strain monoclonal antibody reached 0.6μg / mL and above (2.4μg / ml, 1.2μg / ml, 0.6μg / ml), the three OD values ​​of P30 protein antigen at the same coating concentration were 450nm The value did not change much, indicating that the adsorption of monoclonal antibodies on the ELISA plate reached saturation. When the coating concentration of P30 protein P30-1 strain monoclonal antibody was 0.6μg / mL and the coating concentration of P30 protein antigen was above 0.3μg / mL, the antigen coating reached saturation. Therefore, the optimal coating concentration of P30 protein P30-1 strain monoclonal antibody was determined to be 0.6μg / ml, and the optimal coating concentration of P30 protein antigen was determined to be 0.3μg / ml.

[0091] Example 2

[0092] This example provides the optimization of reaction conditions in the African swine fever virus P30 protein antibody blocking ELISA detection method.

[0093] The specific optimization conditions in this embodiment are: optimization of the optimal working concentration of the HRP enzyme labeled P30 protein P30-2 strain monoclonal antibody, specifically including the following steps:

[0094] (1) Antibody coating: dilute the P30 protein P30-1 monoclonal antibody prepared in Preparation Example 2 to 0.6 μg / mL with 0.05 mol / L carbonate buffer at pH 9.6, add 100 μL to each well of a 96-well ELISA plate, incubate at 4°C for 16 h, and discard the coating solution;

[0095] (2) Washing: Add 300 μL of PBST washing solution to each well, wash three times, discard the liquid in the well, and pat dry;

[0096] (3) Blocking: Add 200 μL of blocking solution to each well and block at 25°C for 60 min. Discard the blocking solution and wash according to the method of step (2);

[0097] (4) Antigen coating: dilute the P30 protein antigen prepared in Preparation Example 1 to 0.3 μg / mL with PBST for capture coating, add 100 μL to each well of a 96-well ELISA plate, incubate at 37° C. for 120 min, discard the liquid in the wells, and wash according to the method of step (2);

[0098] (5) Protection: Add 100 μL of antigen protection solution to each well and protect at 25°C for 60 min. Discard the antigen protection solution and dry.

[0099] (6) Sample addition: dilute the positive control serum and negative control serum prepared in Example 5-6 with sample diluent at a ratio of 1:2, add 100 μL to each well, and incubate at 37° C. for 45 min; discard the liquid in the well, and wash according to the method of step (2);

[0100] (7) Antibody incubation: Use enzyme-labeled antibody diluent to dilute the HRP enzyme-labeled P30 protein P30-2 monoclonal antibody prepared in Preparation Example 4 to 2 μg / ml, 1 μg / ml, 500 ng / ml, 250 ng / ml, 125 ng / ml, and 62.5 ng / ml, respectively, add 100 μL to each well, incubate at 37° C. for 30 min, spin dry, and wash according to the method of step (2);

[0101] (8) Color development: Add 100 μL of TMB substrate solution to each well and develop color at 25°C for 15 min;

[0102] (9) Termination: Add 50 μL of 2 mol / L sulfuric acid stop solution to each well to terminate the color reaction;

[0103] (10) Reading: Use an ELISA reader to read the absorbance of each well at 450 nm and calculate the N / P value (negative control serum OD 450nm Value / positive control serum OD 450nm values), as shown in Table 2.

[0104] Table 2 Optimization results of the best working concentration of HRP enzyme labeled P30 protein P30-2 monoclonal antibody

[0105]

[0106] The enzyme-labeled antibody concentration when the N / P value is the largest is taken as the optimal working concentration.

[0107] By analyzing the optimization results in Table 2, when the concentration of the enzyme-labeled antibody is 500 ng / ml, the N / P value is 9.472, that is, the N / P value at this time is the largest. Therefore, the optimal working concentration of the HRP enzyme-labeled P30 protein P30-2 strain monoclonal antibody is determined to be 500 ng / ml.

[0108] Example 3

[0109] This example provides the optimization of reaction conditions in the African swine fever virus P30 protein antibody blocking ELISA detection method.

[0110] The specific optimization conditions in this embodiment are: optimization of the best dilution of the sample to be tested, specifically including the following steps:

[0111] (1) Antibody coating: dilute the P30 protein P30-1 monoclonal antibody prepared in Preparation Example 2 to 0.6 μg / mL with 0.05 mol / L carbonate buffer at pH 9.6, add 100 μL to each well of a 96-well ELISA plate, incubate at 4°C for 16 h, and discard the coating solution;

[0112] (2) Washing: Add 300 μL of PBST washing solution to each well, wash three times, discard the liquid in the well, and pat dry.

[0113] (3) Blocking: Add 200 μL of blocking solution to each well and block at 25°C for 60 min. Discard the blocking solution and wash according to the method of step (2);

[0114] (4) Antigen coating: dilute the P30 protein antigen prepared in Preparation Example 1 to 0.3 μg / mL with PBST for capture coating, add 100 μL to each well of a 96-well ELISA plate, incubate at 37° C. for 120 min, discard the liquid in the wells, and wash according to the method of step (2);

[0115] (5) Protection: Add 100 μL of antigen protection solution to each well and protect at 25°C for 60 min. Discard the antigen protection solution and dry.

[0116] (6) Sample addition: dilute the positive control serum and negative control serum prepared in Example 5-6 with sample diluent at a ratio of 1:2, 1:5, and 1:10, respectively, add 100 μL to each well, and incubate at 37° C. for 45 min; discard the liquid in the well, and wash according to the method of step (2);

[0117] (7) Antibody incubation: dilute the HRP enzyme-labeled P30 protein P30-2 monoclonal antibody prepared in Preparation Example 4 to 500 ng / ml using enzyme-labeled antibody diluent, add 100 μL to each well, incubate at 37° C. for 30 min, spin dry, and wash according to the method of step (2);

[0118] (8) Color development: Add 100 μL of TMB substrate solution to each well and develop color at 25°C for 15 min;

[0119] (9) Termination: Add 50 μL of 2 mol / L sulfuric acid stop solution to each well to terminate the color reaction;

[0120] (10) Reading: Use an ELISA reader to read the absorbance of each well at 450 nm and calculate the N / P value (negative control serum OD 450nm Value / positive control serum OD 450nm values), as shown in Table 3.

[0121] Table 3 Optimization results of the best dilution of the samples to be tested

[0122]

[0123] The dilution of the sample to be tested when the N / P value is the largest is taken as the optimal dilution.

[0124] By analyzing the optimization results in Table 3, when the serum to be tested is diluted at 1:2, the N / P value is 9.775, that is, the N / P value at this time reaches the maximum. Therefore, the optimal dilution of the serum sample to be tested is determined to be 1:2.

[0125] Example 4

[0126] This example provides the optimization of reaction conditions in the African swine fever virus P30 protein antibody blocking ELISA detection method.

[0127] The specific optimization conditions in this embodiment are: the optimization of the best reaction conditions of the sample to be tested specifically includes the following steps:

[0128] (1) Antibody coating: dilute the P30 protein P30-1 monoclonal antibody prepared in Preparation Example 2 to 0.6 μg / mL with 0.05 mol / L carbonate buffer at pH 9.6, add 100 μL to each well of a 96-well ELISA plate, incubate at 4°C for 16 h, and discard the coating solution;

[0129] (2) Washing: Add 300 μL of PBST washing solution to each well, wash three times, discard the liquid in the well, and pat dry;

[0130] (3) Blocking: Add 200 μL of blocking solution to each well and block at 25°C for 60 min. Discard the blocking solution and wash according to the method of step (2);

[0131] (4) Antigen coating: dilute the P30 protein antigen prepared in Preparation Example 1 to 0.3 μg / mL with PBST for capture coating, add 100 μL to each well of a 96-well ELISA plate, incubate at 37° C. for 120 min, discard the liquid in the wells, and wash according to the method of step (2);

[0132] (5) Protection: Add 100 μL of antigen protection solution to each well and protect at 25°C for 60 min. Discard the antigen protection solution and dry.

[0133] (6) Sample addition: dilute the positive control serum and negative control serum prepared in Preparation Example 5-6 with sample diluent at a ratio of 1:2, add 100 μL to each well, and incubate at 25° C. for 30 min, 25° C. for 45 min, 25° C. for 60 min, 37° C. for 30 min, 37° C. for 45 min, and 37° C. for 60 min, respectively; discard the liquid in the wells, and wash according to the method of step (2);

[0134] (7) Antibody incubation: dilute the HRP enzyme-labeled P30 protein P30-2 monoclonal antibody prepared in Preparation Example 4 to 500 ng / ml using enzyme-labeled antibody diluent, add 100 μL to each well, incubate at 37° C. for 30 min, spin dry, and wash according to the method of step (2);

[0135] (8) Color development: Add 100 μL of TMB substrate solution to each well and develop color at 25°C for 15 min;

[0136] (9) Termination: Add 50 μL of 2 mol / L sulfuric acid stop solution to each well to terminate the color reaction;

[0137] (10) Reading: Use an ELISA reader to read the absorbance of each well at 450 nm and calculate the N / P value (negative control serum OD 450nm Value / positive control serum OD 450nm values), as shown in Table 4.

[0138] Table 4 Optimization results of the best reaction conditions for the samples to be tested

[0139]

[0140] The reaction condition of the sample to be tested when the N / P value is the largest is taken as the optimal reaction condition.

[0141] By analyzing the optimization results in Table 4, when the reaction condition of the sample to be tested is incubated at 37°C for 45 minutes, the N / P value is 10.418, that is, the N / P value at this time reaches the maximum. Therefore, it is determined that the optimal reaction condition of the sample to be tested is incubated at 37°C for 45 minutes.

[0142] Example 5

[0143] This example provides the optimization of reaction conditions in the African swine fever virus P30 protein antibody blocking ELISA detection method.

[0144] The specific optimization conditions in this embodiment are: the optimization of the best reaction conditions of the HRP enzyme labeled P30 protein P30-2 strain monoclonal antibody, specifically including the following steps:

[0145] (1) Antibody coating: dilute the P30 protein P30-1 monoclonal antibody prepared in Preparation Example 2 to 0.6 μg / mL with 0.05 mol / L carbonate buffer at pH 9.6, add 100 μL to each well of a 96-well ELISA plate, incubate at 4°C for 16 h, and discard the coating solution;

[0146] (2) Washing: Add 300 μL of PBST washing solution to each well, wash three times, discard the liquid in the well, and pat dry;

[0147] (3) Blocking: Add 200 μL of blocking solution to each well and block at 25°C for 60 min. Discard the blocking solution and wash according to the method of step (2);

[0148] (4) Antigen coating: dilute the P30 protein antigen prepared in Preparation Example 1 to 0.3 μg / mL with PBST for capture coating, add 100 μL to each well of a 96-well ELISA plate, incubate at 37° C. for 120 min, discard the liquid in the wells, and wash according to the method of step (2);

[0149] (5) Protection: Add 100 μL of antigen protection solution to each well and protect at 25°C for 60 min. Discard the antigen protection solution and dry.

[0150] (6) Sample addition: dilute the positive control serum and negative control serum prepared in Example 5-6 with sample diluent at a ratio of 1:2, add 100 μL to each well, and incubate at 37° C. for 45 min; discard the liquid in the well, and wash according to the method of step (2);

[0151] (7) Antibody incubation: dilute the HRP enzyme-labeled P30 protein P30-2 monoclonal antibody prepared in Preparation Example 4 to 500 ng / ml using enzyme-labeled antibody diluent, add 100 μL to each well, incubate at 25° C. for 30 min, 25° C. for 60 min, 37° C. for 30 min, and 37° C. for 60 min, spin dry, and wash according to the method of step (2);

[0152] (8) Color development: Add 100 μL of TMB substrate solution to each well and develop color at 25°C for 15 min;

[0153] (9) Termination: Add 50 μL of 2 mol / L sulfuric acid stop solution to each well to terminate the color reaction;

[0154] (10) Reading: Use an ELISA reader to read the absorbance of each well at 450 nm and calculate the N / P value (negative control serum OD 450nmValue / positive control serum OD 450nm values), as shown in Table 5.

[0155] Table 5 Optimization results of the best reaction conditions of the P30 protein P30-2 monoclonal antibody labeled with HRP enzyme

[0156]

[0157] The reaction conditions when the N / P value is the largest are taken as the optimal reaction conditions for HRP enzyme labeled P30 protein P30-2 monoclonal antibody.

[0158] By analyzing the optimization results in Table 5, when the reaction conditions of the HRP enzyme-labeled P30 protein P30-2 strain monoclonal antibody are incubated at 37°C for 30 minutes, the N / P value is 9.530, that is, the N / P value at this time reaches the maximum. Therefore, it is determined that the optimal reaction conditions of the HRP enzyme-labeled P30 protein P30-2 strain monoclonal antibody are incubated at 37°C for 30 minutes.

[0159] Example 6

[0160] This embodiment provides an African swine fever virus P30 protein antibody blocking ELISA detection method: the detection method determines the critical value (Cut-off value), the test establishment conditions and the determination method of the P30 protein antibody in the serum sample to be tested.

[0161] In this embodiment, 432 serum samples negative for African swine fever virus antibodies were used as serum samples to be tested, and then the test was performed, which specifically included the following steps:

[0162] (1) Antibody coating: dilute the P30 protein P30-1 monoclonal antibody prepared in Preparation Example 2 to 0.6 μg / mL with 0.05 mol / L carbonate buffer at pH 9.6, add 100 μL to each well of a 96-well ELISA plate, incubate at 4°C for 16 h, and discard the coating solution;

[0163] (2) Washing: Add 300 μL of PBST washing solution to each well, wash three times, discard the liquid in the well, and pat dry;

[0164] (3) Blocking: Add 200 μL of blocking solution to each well and block at 25°C for 60 min. Discard the blocking solution and wash according to the method of step (2);

[0165] (4) Antigen coating: dilute the P30 protein antigen prepared in Preparation Example 1 to 0.3 μg / mL with PBST for capture coating, add 100 μL to each well of a 96-well ELISA plate, incubate at 37° C. for 120 min, discard the liquid in the wells, and wash according to the method of step (2);

[0166] (5) Protection: Add 100 μL of antigen protection solution to each well and protect at 25°C for 60 min. Discard the antigen protection solution and dry.

[0167] (6) Sample addition: dilute the positive control serum, negative control serum and test serum sample prepared in Preparation Example 5-6 with sample diluent at a ratio of 1:2, add 100 μL to each well, and incubate at 37° C. for 45 min; discard the liquid in the well, and wash according to the method of step (2);

[0168] (7) Antibody incubation: dilute the HRP enzyme-labeled P30 protein P30-2 monoclonal antibody prepared in Preparation Example 4 to 500 ng / ml using enzyme-labeled antibody diluent, add 100 μL to each well, incubate at 37° C. for 30 min, spin dry, and wash according to the method of step (2);

[0169] (8) Color development: 100 μL of TMB substrate solution was added to each well and color was developed at 25°C for 15 min;

[0170] (9) Termination: Add 50 μL of 2 mol / L sulfuric acid stop solution to each well to terminate the color reaction;

[0171] (10) Reading: Use an ELISA reader to read the absorbance of each well at 450 nm and calculate the OD of the negative control serum. 450nm Mean and SD values, negative control serum OD 450nm The mean value - 3SD was used as the lowest value for the negative control. The mean and SD values ​​of the positive control serum P / N values ​​were calculated, and the mean value of the positive control serum P / N value + 3SD was used as the highest value for the positive control. The mean and SD values ​​of the sample S / N values ​​were calculated, and the mean value of the sample S / N value - 3SD was used as the negative and positive critical value (Cut-off value).

[0172] The calculation method is as follows:

[0173]

[0174] Through analysis, the optimal cut-off value of the S / N value in the African swine fever virus P30 protein antibody blocking ELISA detection method was 40%.

[0175] Through the above analysis, it can be seen that the experimental establishment conditions in the African swine fever virus P30 protein antibody blocking ELISA detection method provided by the present application are: negative control serum OD 450nm The average value should be >0.7, and the P / N of the positive control serum should be <0.3. The test result is considered valid.

[0176] According to the African swine fever virus P30 protein antibody blocking ELISA detection method provided in the present application, the method for determining the P30 protein antibody in the serum sample to be tested is: when the S / N value of the serum sample to be tested is ≤40%, it is judged as positive; when the S / N value of the serum sample to be tested is >40%, it is judged as negative.

[0177] Test example

[0178] The commercial kits in the experimental examples were purchased from ID-VET, France.

[0179] Test Example 1

[0180] This study investigated the sensitivity of the African swine fever virus P30 protein antibody blocking ELISA detection method.

[0181] Using the detection method provided in Example 6, 10 African swine fever virus P30 protein-positive sera determined by commercial kits and 87 clinically positive sera were used as serum samples to be tested, and then tested to determine the detection sensitivity of the detection method in this application.

[0182] The results showed that the detection results of this detection method were all 10 positive for 10 P30 protein positive sera, and the detection results of 87 clinical positive sera were all positive, with a positive detection rate of 100%, indicating that this method has good sensitivity.

[0183] The prepared P30 protein positive serum was diluted 2-fold as a sample for analytical sensitivity test and compared with the commercial kit. The results showed that the analytical sensitivity of this method for African swine fever virus positive serum was not lower than that of the commercial kit. The above test results show that the detection method in this application has good sensitivity.

[0184] Test Example 2

[0185] This experimental example studied the specificity of the African swine fever virus P30 protein antibody blocking ELISA detection method.

[0186] Using the detection method provided in Example 6, 95 clinical negative sera determined by a commercial kit, classical swine fever virus-positive sera, pseudorabies virus-positive sera, porcine reproductive and respiratory syndrome virus-positive sera, porcine circovirus type 2-positive sera, porcine parvovirus-positive sera, and baculovirus-positive sera were used as serum samples to be tested, and then tested to determine the detection specificity of the detection method in the present application.

[0187] The results showed that the detection results of 95 clinical negative sera, swine fever virus positive sera, porcine pseudorabies virus positive sera, porcine reproductive and respiratory syndrome virus positive sera, porcine circovirus type 2 positive sera, porcine parvovirus positive sera, and baculovirus positive sera were all negative. The above test results show that the detection method provided by the present application has good specificity.

[0188] Test Example 3

[0189] This experimental example studied the repeatability of the African swine fever virus P30 protein antibody blocking ELISA detection method.

[0190] (1) Intra-batch coefficient of variation: Using the detection method provided in Example 6, 10 clinical positive sera determined by commercial kits were tested respectively. Each sample was tested 5 times using the coated plates from the same batch, and the intra-batch coefficient of variation of the detection method in this application was calculated.

[0191] (2) Inter-batch coefficient of variation: Using the detection method provided in this application, 10 clinical positive sera determined using a commercial kit were tested. Each sample was tested using 3 different batches of coated plates, and the inter-batch coefficient of variation of the detection method in this application was calculated.

[0192] Test results: as shown in Table 6.

[0193] Table 6 Results of the repeatability study of the African swine fever virus P30 protein antibody blocking ELISA detection method

[0194] Reproducibility of study results CV value range of 10 positive sera Mean CV value of 10 positive sera The range of CV values ​​between batches 1.51%~5.71% 3.39% Intra-batch CV value range 3.37%~6.33% 3.99%

[0195] By analyzing Table 7, the intra-batch coefficient of variation and the inter-batch coefficient of variation of the detection method in the present application are both no greater than 6.33%. This result shows that the detection method in the present application has good repeatability.

[0196] Example

[0197] Embodiment 7-11

[0198] Examples 7-11 respectively provide an African swine fever virus P30 protein antibody blocking ELISA detection method.

[0199] The difference between the above embodiment and embodiment 6 is that the composition type of the antigen protection solution is different, as shown in Table 7.

[0200] Table 7 Composition of antigen protection solution in Examples 6-11

[0201]

[0202] The preparation method of the antigen protection solution and the African swine fever virus P30 protein antibody blocking ELISA detection method in the above embodiment are the same as those in Example 6.

[0203] Examples 12-16

[0204] Examples 12-16 respectively provide an African swine fever virus P30 protein antibody blocking ELISA detection method.

[0205] The difference between the above embodiment and embodiment 6 is that the type of organic acid in the antigen protection solution is different, as shown below.

[0206] In Example 12: the organic acid is glycine.

[0207] In Example 13, the organic acid is composed of a mixture of oxalic acid and arginine in a weight ratio of 7:2.

[0208] In Example 14, the organic acid is composed of a mixture of oxalic acid and glycine in a weight ratio of 7:4.

[0209] In Example 15, the organic acid is composed of a mixture of oxalic acid and glycine in a weight ratio of 7:1.

[0210] In Example 16, the organic acid is composed of a mixture of oxalic acid and glycine in a weight ratio of 7:3.

[0211] The preparation method of the antigen protection solution and the African swine fever virus P30 protein antibody blocking ELISA detection method in the above embodiment are the same as those in Example 6.

[0212] Comparative Example

[0213] Comparative Examples 1-3

[0214] Comparative Examples 1-3 respectively provide an African swine fever virus P30 protein antibody blocking ELISA detection method.

[0215] The difference between the comparative example and Example 6 is that the composition type of the antigen protection solution is different, as shown in Table 7.

[0216] The preparation method of the antigen protection solution and the African swine fever virus P30 protein antibody blocking ELISA detection method in the above comparative example and Example 6 are the same.

[0217] Comparative Example 4

[0218] This comparative example provides an African swine fever virus P30 protein antibody blocking ELISA detection method.

[0219] The difference between this comparative example and Example 6 is that no antigen protection solution is added, and the specific steps are as follows:

[0220] (1) Antibody coating: dilute the P30 protein P30-1 monoclonal antibody prepared in Preparation Example 2 to 0.6 μg / mL with 0.05 mol / L carbonate buffer at pH 9.6, add 100 μL to each well of a 96-well ELISA plate, incubate at 4°C for 16 h, and discard the coating solution;

[0221] (2) Washing: Add 300 μL of PBST washing solution to each well, wash three times, discard the liquid in the well, and pat dry;

[0222] (3) Blocking: Add 200 μL of blocking solution to each well and block at 25°C for 60 min. Discard the blocking solution and wash according to the method of step (2);

[0223] (4) Antigen coating: dilute the P30 protein antigen prepared in Preparation Example 1 to 0.3 μg / mL with PBST for capture coating, add 100 μL to each well of a 96-well ELISA plate, incubate at 37° C. for 120 min, discard the liquid in the wells, and wash according to the method of step (2);

[0224] (5) Sample addition: dilute the positive control serum, negative control serum and test serum sample prepared in Preparation Example 5-6 with sample diluent at a ratio of 1:2, add 100 μL to each well, and incubate at 37° C. for 45 min; discard the liquid in the well, and wash according to the method of step (2);

[0225] (6) Antibody incubation: dilute the HRP enzyme-labeled P30 protein P30-2 monoclonal antibody prepared in Preparation Example 4 to 500 ng / ml using enzyme-labeled antibody diluent, add 100 μL to each well, incubate at 37° C. for 30 min, spin dry, and wash according to the method of step (2);

[0226] (7) Color development: Add 100 μL of TMB substrate solution to each well and develop color at 25°C for 15 min;

[0227] (8) Termination: Add 50 μL of 2 mol / L sulfuric acid stop solution to each well to terminate the color reaction;

[0228] (9) Reading: Use an ELISA reader to read the absorbance value of each well at a wavelength of 450 nm.

[0229] Test Example 4

[0230] This experiment investigated the sensitivity of the African swine fever virus P30 protein antibody blocking ELISA detection method.

[0231] Using the detection methods provided in Examples 6-16 and Comparative Examples 1-4, the African swine fever virus-positive serum prepared in Preparation Example 5 was used as the serum sample to be tested, and a gradient dilution was performed at 1:8, 1:16, 1:32, 1:64, 1:128, 1:256, 1:512, 1:1024, 1:2048, and 1:4096 times, respectively. Then the test was performed, the S / N value of the serum sample to be tested was calculated, the P30 protein antibody in the serum sample to be tested was determined, and the sensitivity of the detection method in the present application was investigated.

[0232] Test results: as shown in Table 8.

[0233] Table 8 Sensitivity test results of the detection methods in Examples 6-16 and Comparative Examples 1-4

[0234]

[0235] From the test results in Table 8, it can be seen that when the detection method provided by the present application is used to detect P30 protein antibodies in gradient diluted positive serum, the present application uses specific amounts of propylene glycol, trehalose, sodium glutamate, recombinant Escherichia coli thioredoxin, juglone, organic acid and water as raw materials for the antigen protection liquid, protects the standard antigen, and then detects P30 protein antibodies in the serum sample to be tested, which can significantly improve the detection sensitivity of the detection method.

[0236] Test Example 5

[0237] This experimental example studied the stability of the African swine fever virus P30 protein antibody blocking ELISA detection method.

[0238] The clinical positive sera determined by commercial kits were tested using the detection methods provided in Examples 6-16 and Comparative Examples 1-4. Each sample was tested 5 times using the coated plates from the same batch, and the intra-batch coefficient of variation of the detection method was calculated.

[0239] Test results: as shown in Table 9.

[0240] Table 9 Stability test results of the detection methods in Examples 6-16 and Comparative Examples 1-4

[0241]

[0242] Combined with the test results in Table 9, the present application uses a specific amount of glycerol, trehalose, sodium glutamate, recombinant Escherichia coli thioredoxin, juglone, organic acid and water as an antigen protection solution to protect the standard antigen, and then detects the P30 protein antibody in the serum sample to be tested, which can make the intra-batch coefficient of variation CV value less than 6.3%. The above test results show that the use of the antigen protection solution provided by the present application can significantly improve the stability of the African swine fever virus P30 protein antibody blocking ELISA detection method.

[0243] In Comparative Example 4, no antigen protection solution was used, and the intra-batch coefficient of variation of the detection method was 19.87%, indicating that the stability of the detection method was poor.

[0244] By comparing the test results of Examples 6-11 with those of Comparative Examples 1-3, the amount of each component in the antigen protection solution has a great influence on the coefficient of variation of the detection method. The present application chooses to further improve the stability of the detection method by reasonably controlling the amount of each raw material in the antigen protection solution.

[0245] By comparing the detection results of Examples 6, 12-16, the present application selects a mixture of oxalic acid and glycine in a weight ratio of 7:1-3 to form an organic acid as the raw material composition in the antigen protection solution, which can further improve the stability of the detection method.

[0246] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements may be made thereto based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.

Claims

1. A blocking ELISA detection kit for African swine fever virus P30 protein antibodies, It is characterized in that The detection kit includes capture antibody, standard antigen, enzyme-labeled antibody, and antigen protection solution; The antigen protection solution is composed of the following components: Composition: 80-100 parts of glycerol, 4-8 parts of trehalose, 0.1-0.2 parts of recombinant Escherichia coli thioredoxin, 0.01-0.09 parts of sodium glutamate, 0.01-0.08 parts of juglone, 0.7-1.8 parts of organic acid, 800-900 parts of water; the organic acid is oxalic acid and glycine in a weight ratio of 7:1-3.

2. The blocking ELISA detection kit for African swine fever virus P30 protein antibody according to claim 1, It is characterized in that The antigen protection solution specifically comprises the following components in concentrations: 85-95 parts of glycerol, 5-7 parts of trehalose, 0.12-0.18 parts of recombinant Escherichia coli thioredoxin, 0.05-0.09 parts of sodium glutamate, 0.01-0.04 parts of juglone, 0.9-1.5 parts of organic acid, and 800-900 parts of water.

3. The blocking ELISA detection kit for African swine fever virus P30 protein antibody according to claim 1, It is characterized in that The detection kit also includes a positive control serum, a negative control serum, a sample diluent, an enzyme-labeled antibody diluent, a washing solution, a blocking solution, a TMB substrate solution, and a stop solution.

4. The blocking ELISA detection kit for African swine fever virus P30 protein antibody according to claim 1, It is characterized in that The coating concentration of the capture antibody is 0.15-2.4 μg / mL; the coating concentration of the standard antigen is 0.0375-1.2 μg / mL; and the concentration of the enzyme-labeled antibody is 62.5-2000 ng / ml.

5. The blocking ELISA detection kit for African swine fever virus P30 protein antibody according to claim 3, It is characterized in that The sample diluent is 0.4-0.6wt% PBSA; the enzyme-labeled antibody diluent is PBSA containing 0.4-0.6wt% sucrose and a concentration of 0.4-0.6wt%; and the blocking solution is 2.5-3.5wt% BSA.

6. A blocking ELISA method for detecting antibodies against the P30 protein of African swine fever virus for non-diagnostic purposes, It is characterized in that The detection method is obtained based on the blocking ELISA detection kit for the African swine fever virus P30 protein antibody according to any one of claims 1 to 5.

7. A non-diagnostic African swine fever virus P30 protein antibody blocking ELISA detection method according to claim 6, It is characterized in that The following steps are involved: (1) Antibody coating: dilute the capture antibody with carbonate buffer, add 80-120 μL to each well of the ELISA plate, incubate at 2-8°C for 14-20 hours, and discard the coating solution; (2) Washing: Add the washing solution to each well for washing, discard the liquid in the well, and pat dry; (3) Blocking: Add 180-220 μL of the blocking solution to each well, block at 23-27°C for 40-80 min, discard the blocking solution, and wash according to the method of step (2); (4) Antigen coating: dilute the standard antigen with PBST, add 80-120 μL to each well of the ELISA plate, incubate at 35-39°C for 100-140 min, discard the liquid in the well, and wash according to the method of step (2); (5) Protection: Add 70-130 μL of the antigen protection solution to each well, protect at 23-39°C for 20-70 min, discard the antigen protection solution, and dry; (6) Sample addition: Use the sample diluent to dilute the positive control serum, the negative control serum, and the test serum sample, respectively, add 80-120 μL to each well for incubation, then discard the liquid in the well and wash according to the method of step (2); (7) Antibody incubation: dilute the enzyme-labeled antibody using the enzyme-labeled antibody diluent, add 80-120 μL to each well for incubation, incubate at 35-39° C. for 20-40 min, then spin dry, and wash according to the method of step (2); (8) Color development: Add 80-120 μL of the TMB substrate solution to each well and incubate at 25°C for color development; (9) Termination: Add 40-60 μL of the stop solution to each well to terminate the reaction; (10) Reading: Use an ELISA reader to read the absorbance of each well at a wavelength of 450 nm.

8. A non-diagnostic African swine fever virus P30 protein antibody blocking ELISA detection method according to claim 7, It is characterized in that After adding the antigen protection solution in step (5), protect at 23-27° C. for 50-70 minutes.